Preservation of cortical histamine H3 receptors in ischemic vascular and mixed dementias

Journal of the Neurological Sciences

Volumn 315, Issue 1-2, 2012, Pages 110-114

  Sheng, Yuan ^a,b   Lee, Jasinda H ^a,b   Medhurst, Andrew D ^c,e   Wilcock, Gordon K ^d   Esiri, Margaret ^d   Wong, Peter T H ^a,b   Chen, Christopher P ^a,b   Lai, Mitchell K P ^a,b  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c GLAXOSMITHKLINE   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e BioFocus DPI   (United Kingdom)

Author keywords

Alzheimer's disease; Hippocampus; Histamine H3 receptors; Mixed dementia; Neocortex; Subcortical ischemic vascular dementia

Indexed keywords

HISTAMINE H3 RECEPTOR; RADIOLIGAND;

AGED; ANTERIOR CINGULATE; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DEMENTIA; FEMALE; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; ISCHEMIC VASCULAR DEMENTIA; MALE; MINI MENTAL STATE EXAMINATION; MIXED DEMENTIA; PRIORITY JOURNAL; RADIOASSAY; SCORING SYSTEM;

AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CEREBRAL CORTEX; DEMENTIA; DEMENTIA, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PROTEIN BINDING; RECEPTORS, HISTAMINE H3;

EID: 84857993596     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2011.11.013     Document Type: Article

References (40)

1. Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K, et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol 2008;7(9):812-26.
2. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54(11 Suppl 5):S4-9. (Pubitemid 30390598)
3. Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43(2):250-60. (Pubitemid 23060253)
4. Wallin A, Milos V, Sjogren M, Pantoni L, Erkinjuntti T. Classification and subtypes of vascular dementia. Int Psychogeriatr 2003;15(Suppl. 1):27-37. (Pubitemid 37175164)
5. Román GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC. Subcortical ischaemic vascular dementia. Lancet Neurol 2002;1(7):426-36. (Pubitemid 37159153)
6. Chui HC. Subcortical ischemic vascular dementia. Neurol Clin 2007;25(3):717-40. (Pubitemid 47061503)
7. Jellinger KA, Attems J. Neuropathological evaluation of mixed dementia. J Neurol Sci 2007;257(1-2):80-7. (Pubitemid 46856518)
8. Francis PT, Ramírez MJ, Lai MK. Neurochemical basis for symptomatic treatment of Alzheimer's disease. Neuropharmacology 2010;59:221-9.
9. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002;162(18):2046-52. (Pubitemid 35168212)
10. Keverne JS, Low WC, Ziabreva I, Court JA, Oakley AE, Kalaria RN. Cholinergic neuronal deficits in CADASIL. Stroke 2007;38(1):188-91. (Pubitemid 46035626)
11. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 2007;6(9):782-92. (Pubitemid 47243710)
12. Kirvell SL, Elliott MS, Kalaria RN, Hortobagyi T, Ballard CG, Francis PT. Vesicular glutamate transporter and cognition in stroke: a case-control autopsy study. Neurology 2010;75(20):1803-9.
13. Mohamed NE, Zhao Y, Lee JH, Tan MG, Esiri MM, Wilcock GK, et al. Upregulation of AMPA receptor GluR2 (GluA2) subunits in subcortical ischemic vascular dementia is repressed in the presence of Alzheimer's disease. Neurochem Int 2011;58:820-5.
14. Wilcock GK. Memantine for the treatment of dementia. Lancet Neurol 2003;2(8):503-5. (Pubitemid 36876107)
15. Haas HL, Sergeeva OA, Selbach O. Histamine in the nervous system. Physiol Rev 2008;88(3):1183-241.
16. Brown RE, Stevens DR, Haas HL. The physiology of brain histamine. Prog Neurobiol 2001;63(6):637-72. (Pubitemid 32119421)
17. Arrang JM, Garbarg M, Schwartz JC. Auto-inhibition of brain histamine release-mediated by a novel class (H3) of histamine receptor. Nature 1983;302(5911):832-7. (Pubitemid 13125123)
18. Schlicker E, Malinowska B, Kathmann M, Göthert M. Modulation of neurotransmitter release via histamine H3 heteroreceptors. Fundam Clin Pharmacol 1994;8(2):128-37. (Pubitemid 24103046)
19. Blandina P, Giorgetti M, Bartolini L, Cecchi M, Timmerman H, Leurs R, et al. Inhibition of cortical acetylcholine release and cognitive performance by histamine H3 receptor activation in rats. Br J Pharmacol 1996;119(8):1656-64. (Pubitemid 27019542)
20. Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB, et al. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl} -benzofuran-5-yl) benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther 2005;313(1):176-90. (Pubitemid 40411341)
21. Medhurst AD, Atkins AR, Beresford IJ, Brackenborough K, Briggs MA, Calver AR, et al. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther 2007;321(3):1032-45. (Pubitemid 46762709)
22. Galici R, Boggs JD, Aluisio L, Fraser IC, Bonaventure P, Lord B, et al. JNJ-10181457, a selective non-imidazole histamine H(3) receptor antagonist, normalizes acetylcholine neurotransmission and has efficacy in translational rat models of cognition. Neuropharmacology 2009;56(8):1131-7.
23. Bardgett ME, Davis NN, Schultheis PJ, Griffith MS. Ciproxifan, an H3 receptor antagonist, alleviates hyperactivity and cognitive deficits in the APP Tg2576 mouse model of Alzheimer's disease. Neurobiol Learn Mem 2011;95(1):64-72.
24. Brioni JD, Esbenshade TA, Garrison TR, Bitner SR, CowartMD. Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease. J Pharmacol Exp Ther 2011;336(1):38-46.
25. Hancock AA, Fox GB. Perspectives on cognitive domains, H3 receptor ligands and neurological disease. Expert Opin Investig Drugs 2004;13(10):1237-48. (Pubitemid 39359655)
26. Medhurst AD, Roberts JC, Lee J, Chen CP, Brown SH, Roman S, et al. Characterization of histamine H(3) receptors in Alzheimer's Disease brain and amyloid overexpressing TASTPM mice. Br J Pharmacol 2009;157:130-8.
27. Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S, et al. CAMDEX. A standardised instrument for the diagnosis ofmental disorder in the elderlywith special reference to the early detection of dementia. Br J Psychiatry 1986;149:698-709. (Pubitemid 17205276)
28. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12(3):189-98.
29. de Koning I, van Kooten F, Dippel DW, van Harskamp F, Grobbee DE, Kluft C, et al. The CAMCOG: a useful screening instrument for dementia in stroke patients. Stroke 1998;29(10):2080-6. (Pubitemid 28443522)
30. Kalaria RN, Kenny RA, Ballard CG, Perry R, Ince P, Polvikoski T. Towards defining the neuropathological substrates of vascular dementia. J Neurol Sci 2004;226(1-2):75-80. (Pubitemid 39505411)
31. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortiumto Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41(4):479-86.
32. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82(4):239-59.
33. Lai MK, Tsang SW, Esiri MM, Francis PT, Wong PT, Chen CP. Differential involvement of hippocampal serotonin1A receptors and re-uptake sites in noncognitive behaviors of Alzheimer's disease. Psychopharmacology (Berl) 2011;213(2-3):431-9.
34. McPherson GA. Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC. J Pharmacol Methods 1985;14(3):213-28. (Pubitemid 15241175)
35. Lai MK, Tsang SW, Alder JT, Keene J, Hope T, Esiri MM, et al. Loss of serotonin 5- HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer's disease. Psychopharmacology (Berl) 2005;179(3):673-7. (Pubitemid 40674769)
36. Lee JH, Agacinski G, Williams JH, Wilcock GK, Esiri MM, Francis PT, et al. Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex. Neurochem Int 2010;57(8):985-9.
37. Martinez-Mir MI, Pollard H, Moreau J, Arrang JM, Ruat M, Traiffort E, et al. Three histamine receptors (H1, H2 and H3) visualized in the brain of human and nonhuman primates. Brain Res 1990;526(2):322-7. (Pubitemid 20307895)
38. Gemkow MJ, Davenport AJ, Harich S, Ellenbroek BA, Cesura A, Hallett D. The histamine H3 receptor as a therapeutic drug target for CNS disorders. Drug Discov Today 2009;14(9-10):509-15.
39. Ashworth S, Rabiner EA, Gunn RN, Plisson C,Wilson AA, Comley RA, et al. Evaluation of 11C-GSK189254 as a novel radioligand for the H3 receptor in humans using PET. J Nucl Med 2010;51(7):1021-9.
40. Bitner RS, Markosyan S, Nikkel AL, Brioni JD. In-vivo histamine H(3) receptor antagonism activates cellular signaling suggestive of symptomatic and disease modifying efficacy in Alzheimer's disease. Neuropharmacology 2011;60(2-3):460-6.